ArticleCureus2026
CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are currently in widespread use for the treatment of both advanced metastatic and early-stage hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)- negative breast cancer. Clinical studies in the metastatic setting have demonstrated a survival benefit with the use of ribociclib. Both abemaciclib and ribociclib have shown significant improvements in invasive disease-free survival in high-risk early-stage breast cancer. Hematologic adverse events are well characterized with the three currently approved CDK4/6 inhibitors, namely palbociclib, abemaciclib, and ribociclib. Among non-hematologic toxicities, there is a paucity of information regarding cutaneous adverse events related to these three medications. In this case report, we seek to describe the incidence, time to onset, and management of CDK4/6-mediated cutaneous adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.